Phio Pharmaceuticals to Present at Biotech Showcase 2020HomeMailNewsFinanceSportsEntertainmentSearchMobileMore...YAHOO_FINANCESearchSign inMailSign in to view your mailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets closedS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)Phio Pharmaceuticals to Present at Biotech Showcase 2020PR NewswireJanuary 6, 2020ReblogShareTweetShare- Management will be hosting meetings at the LifeSci Advisors Corporate Access Event in San Francisco during the weekMARLBOROUGH, Mass., Jan. 6, 2020 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, announced today that its chief executive officer, Dr. Gerrit Dispersyn, will present at Biotech Showcase™ 2020 on Monday, January 13, 2020 at 2:00 pm Pacific Time at the Hilton San Francisco Union Square. Phio will also be hosting institutional investor and partnering meetings at the LifeSci Advisors Corporate Access Event being held at the Sir Francis Drake Hotel in San Francisco from January 13-15, 2020.Logo - https://mma.prnewswire.com/media/786567/Phio_Pharmaceuticals_Logo.jpg During the presentation at Biotech Showcase, Dr. Dispersyn will discuss Phio's proprietary gene-silencing technology INTASYLTM and provide updates on its broad early-stage pipeline applying INTASYL™ both as a standalone therapy and in combination with adoptive cell-therapy.  This will include updates on the Company's lead product candidates PH-762, designed to silence PD-1 receptor expression on T cells, and PH-804, designed to silence expression of TIGIT on T cells and NK cells.Details of the presentation are as follows: Date:
Monday, January 13, 2020
Time:
2:00 p.m. (PST)
Track:
Yosemite C (Ballroom Level)
Location:
Hilton San Francisco Union Square
A live audio webcast of the presentation will be made available on the Events section of the Company's website at http://investors.phiopharma.com/events-and-presentations/events with a replay accessible following the live presentation.To schedule a meeting with the Phio management team, please register online here or by email to access@lifesciadvisors.com.About Phio Pharmaceuticals Corp.Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (INTASYL™) therapeutic platform. The Company's efforts are focused on silencing tumor-induced suppression of the immune system through its proprietary INTASYL™ platform with utility in immune cells and/or the tumor micro-environment. Our goal is to develop powerful INTASYL™ therapeutic compounds that can weaponize immune effector cells to overcome tumor immune escape, thereby providing patients a powerful new treatment option that goes beyond current treatment modalities. For additional information, visit the Company's website, www.phiopharma.com.Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. These statements are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, the safety and efficacy of our product candidates, future success of our clinical trials and scientific studies, expected duration of available cash runway, our ability to enter into strategic partnerships and the future success of these strategic partnerships, the availability of funds and resources to pursue our research and development projects and general economic conditions. Our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q include detailed risks under the caption "Risk Factors" that may affect our business, results of operations and financial condition. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release. ContactPhio Pharmaceuticals Corp.ir@phiopharma.com Investor Contact Ashley R. Robinson LifeSci Advisors arr@lifesciadvisors.comCisionMoreView original content:http://www.prnewswire.com/news-releases/phio-pharmaceuticals-to-present-at-biotech-showcase-2020-300981037.htmlSOURCE Phio Pharmaceuticals Corp.ReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextFacebook Cancels Annual Conference Due to Coronavirus Concerns: 'This Was a Tough Call to Make'People'Dispatches From Elsewhere': a crazy real-life 'game' comes to TVAFPCoronavirus Infects Wall Street — Can Gilead, Moderna Ride To The Rescue?Investor's Business DailyWhy This Small Gene Therapy Player Rocketed On A Biogen DealInvestor's Business DailyOtonomy (OTIC) Reports Q4 Loss, Misses Revenue EstimatesZacksRichard Branson’s Wealth Falls to Earth as Virgin Galactic SputtersBloombergA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoBiocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance VideoFed seen cutting rates amid virus threat, low inflationReutersStock market live updates: Dow drops 1190 points amid coronavirus fears, S&P 500 sees fastest correction in historyYahoo FinanceMost face masks won’t protect you from the coronavirusYahoo FinanceDon’t buy the stock dip yet, says Goldman as it warns coronavirus will wipe out earnings growth this yearMarketWatchCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance Video